PRL and breast carcinoma: The four new AKT1m transcripts were initially cloned from prolactin-responsive T47-D breast cancer cells, but the analyses of a larger panel of breast cancer cells as well as primary tumors show that expression of AKT1m is not restricted to luminal-type cancer cells.